Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating reaffirmed by equities researchers at Wells Fargo & Co in a research note issued to investors on Thursday. They presently have a $20.00 target price on the stock, down from their previous target price of $24.00. Wells Fargo & Co‘s price objective indicates a potential upside of 15.61% from the company’s current price. The analysts noted that the move was a valuation call.
A number of other equities analysts have also issued reports on TEVA. Zacks Investment Research raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Monday, December 3rd. ValuEngine cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Oppenheimer reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Monday. Royal Bank of Canada set a $22.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Friday, November 2nd. Finally, Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday, November 1st. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $22.39.
Shares of NYSE TEVA traded down $0.33 during mid-day trading on Thursday, reaching $17.30. The company had a trading volume of 16,212,911 shares, compared to its average volume of 10,017,625. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The stock has a market cap of $19.44 billion, a PE ratio of 4.40, a PEG ratio of 5.83 and a beta of 1.46. Teva Pharmaceutical Industries has a 52 week low of $14.59 and a 52 week high of $25.96.
In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 1,643 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, January 2nd. The stock was sold at an average price of $15.70, for a total transaction of $25,795.10. Following the sale, the vice president now owns 13,469 shares of the company’s stock, valued at approximately $211,463.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Notaristefani Carlo De sold 5,041 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $17.88, for a total value of $90,133.08. Following the sale, the vice president now directly owns 17,162 shares in the company, valued at approximately $306,856.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,617 shares of company stock valued at $136,230. Insiders own 0.43% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Brahman Capital Corp. grew its stake in Teva Pharmaceutical Industries by 67.3% in the fourth quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock valued at $188,866,000 after purchasing an additional 4,925,245 shares in the last quarter. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries by 19.1% during the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after acquiring an additional 3,921,785 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its position in shares of Teva Pharmaceutical Industries by 6,156.1% during the 4th quarter. Menora Mivtachim Holdings LTD. now owns 3,658,479 shares of the company’s stock worth $56,414,000 after purchasing an additional 3,600,000 shares during the last quarter. Beck Mack & Oliver LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $64,484,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 99.9% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,715,499 shares of the company’s stock worth $88,133,000 after purchasing an additional 2,855,802 shares during the last quarter. Institutional investors and hedge funds own 62.11% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Put Option
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.